Indications and uses
treats migraine
treats migraine
do not use more than directed adults: take 2 tablets with a glass of water if symptoms persist or worsen, ask your doctor do not take more than 2 tablets in 24 hours, unless directed by a doctor under 18 years of age: ask a doctor
store at controlled room temperature 20°-25°C (68°-77°F) read all product information before using. Keep this box for important information. TAMPER-EVIDENT BOTTLE DO NOT USE IF INNER FOIL SEAL IMPRINTED WITH “SEALED for YOUR PROTECTION”IS BROKEN OR MISSING
Acetaminophen 250 mg
Aspirin 250 mg (NSAID) *
Caffeine 65 mg
* nonsteroidal anti-inflammatory drug
Pain reliever
Pain reliever
Pain reliever aid
Reye’s syndrome: Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. When using this product, if changes in behavior with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of Reye’s syndrome, a rare but serious illness.
Allergy alert: Aspirin may cause a severe allergic reaction which may include:
Liver warning: This product contains acetaminophen. Severe liver damage may occur if you take
Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you
Caffeine warning: The recommended dose of this product contains about as much caffeine as a cup of coffee. Limit the use of caffeine-containing medications, foods, or beverages while taking this product because too much caffeine may cause nervousness, irritability, sleeplessness, and, occasionally, rapid heart beat.
ask a health professional before use. It is especially important not to use aspirin during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
In case of overdose, get medical help or contact a Poison Control Center right away. Quick medical attention is critical for adults as well as for children even if you do not notice any signs or symptoms.
TAMPER-EVIDENT BOTTLE
DO NOT USE IF INNER FOIL SEAL IMPRINTED WITH
“SEALED for YOUR PROTECTION”IS BROKEN OR MISSING
benzoic acid, carnauba wax, FD&C blue #1, hydroxypropylcellulose, hypromellose, light mineral oil, microcrystalline cellulose, polysorbate 20, povidone, propylene glycol, simethicone emulsion, sorbitan monolaurate, stearic acid, titanium dioxide
This product is supplied by State of Florida DOH Central Pharmacy as follows:
| NDC | Strength | Quantity/Form | Color | Source Prod. Code |
| 53808-0835-1 | 250 mg / 250 mg / 65 mg | 30 Tablets in a Blister Pack | White | 0067-2039 |
This product was distributed By:
Novartis Consumer Health, Inc.
Parsippany, NJ 07054-0622
1-800-468-7746
And Repackaged By:
State of Florida DOH Central Pharmacy
104-2 Hamilton Park Drive
Tallahassee, FL 32304
United States
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 308297 | acetaminophen 250 MG / aspirin 250 MG / caffeine 65 MG Oral Tablet | PSN | 1 |
| 209468 | EXCEDRIN 250 MG / 250 MG / 65 MG Oral Tablet | PSN | 1 |
| 209468 | acetaminophen 250 MG / aspirin 250 MG / caffeine 65 MG Oral Tablet [Excedrin] | SBD | 1 |
| 308297 | acetaminophen 250 MG / aspirin 250 MG / caffeine 65 MG Oral Tablet | SCD | 1 |
| 308297 | APAP 250 MG / ASA 250 MG / caffeine 65 MG Oral Tablet | SY | 1 |
| 209468 | APAP 250 MG / ASA 250 MG / Caffeine 65 MG Oral Tablet [Excedrin] | SY | 1 |
| 209468 | Excedrin Extra Strength (APAP 250 MG / ASA 250 MG / caffeine 65 MG) Oral Tablet | SY | 1 |
| 209468 | Excedrin Menstrual Complete (APAP 250 MG / ASA 250 MG / caffeine 65 MG) Oral Tablet | SY | 1 |
| 209468 | Excedrin Migraine (APAP 250 MG / ASA 250 MG / caffeine 65 MG) Oral Tablet | SY | 1 |
| Class | Version | Type | Effective |
|---|---|---|---|
| ASPIRIN Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20191108 |
| CAFFEINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 53808-0835-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9cf-f794-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 53808-0835-1 | EXCEDRINMIGRAINE | 30 in 1 BLISTER PACK | TABLET, FILM COATED | 30 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 53808-0835 | EXCEDRIN MIGRAINE (ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] | 1 | Legacy NDC, 1 package rows | 20140409_540c34a3-a4dc-4dd7-8ef9-53092b7a86bb.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0067-2039-08 | EA - Each | 0067-2039 | 16ce8a4b-bd70-4a64-ad07-8ff387eb6638 | 1 | 2012-07-24 |
| 0067-2039-24 | EA - Each | 0067-2039 | bbb39c99-180a-437a-85d0-e53a1eb91ead | 1 | 2012-07-24 |
| 0067-2039-33 | EA - Each | 0067-2039 | 7b55aa5b-c0f7-4ea7-b9a8-55228dc5e474 | 1 | 2014-09-03 |
| 0067-2039-50 | EA - Each | 0067-2039 | 22e8dd78-54d4-44ec-a754-b64ce6da0b27 | 1 | 2012-07-24 |
| 0067-2039-77 | EA - Each | 0067-2039 | e7beb6f2-112b-44d1-bc0c-8cc047750441 | 1 | 2012-07-24 |
| 0067-2039-83 | EA - Each | 0067-2039 | aeb6329a-c0f6-4dbe-89e3-ff583f2b8adc | 1 | 2024-04-05 |
| 0067-2039-86 | EA - Each | 0067-2039 | dfab005f-c6a2-4e68-af6a-5340d2fe2e83 | 1 | 2015-10-02 |
| 0067-2039-91 | EA - Each | 0067-2039 | baa7e6be-1a22-4946-bd6d-398153fc0397 | 1 | 2012-07-24 |
| 0067-2039-92 | EA - Each | 0067-2039 | 517a3c30-8e99-41dd-8798-e5871b87f0ac | 1 | 2015-02-02 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ACETAMINOPHEN | ACTIVE INGREDIENT | 362O9ITL9D | 1 | |
| ASPIRIN | ACTIVE INGREDIENT | R16CO5Y76E | 1 | |
| CAFFEINE | ACTIVE INGREDIENT | 3G6A5W338E | 1 | |
| ACETAMINOPHEN | ACTIVE MOIETY | 362O9ITL9D | 1 | |
| ASPIRIN | ACTIVE MOIETY | R16CO5Y76E | 1 | |
| CAFFEINE | ACTIVE MOIETY | 3G6A5W338E | 1 | |
| BENZOIC ACID | INACTIVE INGREDIENT | 8SKN0B0MIM | 1 | |
| CARNAUBA WAX | INACTIVE INGREDIENT | R12CBM0EIZ | 1 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 1 | |
| FD&C BLUE NO. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 1 | |
| HYDROXYPROPYL CELLULOSE | INACTIVE INGREDIENT | RFW2ET671P | 1 | |
| HYPROMELLOSE 2208 (100000 MPA.S) | INACTIVE INGREDIENT | VM7F0B23ZI | 1 | |
| LIGHT MINERAL OIL | INACTIVE INGREDIENT | N6K5787QVP | 1 | |
| POLYSORBATE 20 | INACTIVE INGREDIENT | 7T1F30V5YH | 1 | |
| POVIDONE | INACTIVE INGREDIENT | FZ989GH94E | 1 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| SORBITAN MONOLAURATE | INACTIVE INGREDIENT | 6W9PS8B71J | 1 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 1 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 53808-0835 | 53808-0835-1 |
| 0067-2039 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, FILM COATED / ORAL | 0.16 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, FILM COATED / ORAL | 176 mg | ||
| HYPROMELLOSE 2208 (100000 MPA.S) | HYPROMELLOSE 2208 (100000 MPA.S) | VM7F0B23ZI | CAPSULE / ORAL | 161 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | TABLET, FILM COATED / ORAL | 0.35 mg | ||
| SORBITAN MONOLAURATE | SORBITAN MONOLAURATE | 6W9PS8B71J | TABLET, FILM COATED / ORAL | 800 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| BENZOIC ACID | BENZOIC ACID | 8SKN0B0MIM | TABLET, FILM COATED / ORAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, FILM COATED / ORAL | 36 mg | ||
| HYPROMELLOSE 2208 (100000 MPA.S) | HYPROMELLOSE 2208 (100000 MPA.S) | VM7F0B23ZI | TABLET, EXTENDED RELEASE / ORAL | 2147 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| HYPROMELLOSE 2208 (100000 MPA.S) | HYPROMELLOSE 2208 (100000 MPA.S) | VM7F0B23ZI | TABLET / ORAL | 1296 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, FILM COATED / ORAL | 131.67 mg | ||
| HYPROMELLOSE 2208 (100000 MPA.S) | HYPROMELLOSE 2208 (100000 MPA.S) | VM7F0B23ZI | CAPSULE, EXTENDED RELEASE / ORAL | 900 mg | ||
| HYPROMELLOSE 2208 (100000 MPA.S) | HYPROMELLOSE 2208 (100000 MPA.S) | VM7F0B23ZI | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 1320 mg | ||
| CARNAUBA WAX | CARNAUBA WAX | R12CBM0EIZ | TABLET, FILM COATED / ORAL | 1 mg | ||
| LIGHT MINERAL OIL | LIGHT MINERAL OIL | N6K5787QVP | TABLET, FILM COATED / ORAL | 2.49 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | ACETAMINOPHEN; ASPIRIN; CAFFEINE | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N020802-001 | EXCEDRIN (MIGRAINE RELIEF) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N020802-001 | EXCEDRIN (MIGRAINE) | 250MG;250MG;65MG | TABLET / ORAL | RLD, RS | 1998-01-14 | 3a93d1ddd44b… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| EXCEDRIN MIGRAINE | ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE | Haleon US Holdings LLC | 7ed841fb-a61c-4868-b4e5-4f2311a5e79c | 2025-06-25 | Warnings | 0067-2039 |
| b7ef153b-d459-49e9-ac4a-c7744a7fc9ed | 540c34a3-a4dc-4dd7-8ef9-53092b7a86bb | 2013-09-11 | Boxed warning, Warnings | b7ef153b-d459-49e9-ac4a-c7744a7fc9ed 540c34a3-a4dc-4dd7-8ef9-53092b7a86bb |
Adverse event summaries are temporarily unavailable. Other product information remains available.